 |
Quick Links |
| Information by Disease |
|
|
 |
| Cancer News |
|
|
 |
| Conference Coverage |
|
|
 |
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
 |

Conference Coverage
A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists: Updates in the Management of Gynecologic Cancers Krishnansu S Tewari, MD, FACOG, FACS
|
| |
Current Topics
|
|
|
Latest
Cervical Cancer
News
Primary Care Physicians May Be Ordering More Pap Smears Than Necessary (11/13/2009) Researchers from the National Institutes of Health have reported that primary care physicians overuse Pap smear testing and are not following current recommendations. The details of this study appeared in the November 3, 2009 issue of the Annals of Internal Medicine.
Vaccination for HPV in Females Associated with a Decline in Genital Warts in Females and Males (10/29/2009) Researchers from Australia have reported a decline in the number of cases of genital warts in women and men since the initiation of quadrivalent vaccination to prevent human papillomavirus (HPV) infection. The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 16, 2009.
Knowledge Deficits Limit Use of HPV Vaccine in Young Women (10/29/2009) Researchers from Roswell Park Cancer Institute, Upstate Medical University and the State University of New York at Buffalo have reported that knowledge and risk perceptions among college students limits vaccination for human papillomavirus (HPV). The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 19, 2009.
HPV Vaccination Not Cost-effective for Women over 30 Years of Age (10/28/2009) Researchers from the Harvard School of Public Health have reported that human papillomavirus vaccination for prevention of cervical cancer is not cost-effective in women between the ages of 35 and 45 years. The details of this report appeared in the October 20, 2009 issue of the Annals of Internal Medicine.
CDC Panel Rejects Routine Vaccination of Boys with Gardasil® but Approves use for Preventing Genital Warts (10/26/2009) On September 9, 2009, a U.S. FDA advisory panel voted for approval of the use of Gardasil® for the prevention of genital warts in males ages nine through 16. The age range was based on safety data for this age group. However, another U.S. FDA advisory panel, on 10/21/2009, voted against the routine use of Gardasil for vaccination of all young boys.
More Cervical Cancer News »
|
|
Newsletters
Register in our member center today to receive a monthly newsletter with clinical
news, conference coverage, and current topic updates.
|
|
|
|
|
|